JP2023522307A5 - - Google Patents
Info
- Publication number
- JP2023522307A5 JP2023522307A5 JP2022559709A JP2022559709A JP2023522307A5 JP 2023522307 A5 JP2023522307 A5 JP 2023522307A5 JP 2022559709 A JP2022559709 A JP 2022559709A JP 2022559709 A JP2022559709 A JP 2022559709A JP 2023522307 A5 JP2023522307 A5 JP 2023522307A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- schizophrenia
- group
- compound
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001640P | 2020-03-30 | 2020-03-30 | |
| US63/001,640 | 2020-03-30 | ||
| PCT/EP2021/058099 WO2021198149A1 (en) | 2020-03-30 | 2021-03-29 | Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522307A JP2023522307A (ja) | 2023-05-30 |
| JP2023522307A5 true JP2023522307A5 (cg-RX-API-DMAC7.html) | 2024-05-23 |
| JP7617134B2 JP7617134B2 (ja) | 2025-01-17 |
Family
ID=75362607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559709A Active JP7617134B2 (ja) | 2020-03-30 | 2021-03-29 | Gpr52アゴニスト活性を有する置換3-フェノキシアゼチジン-1-イル-ピラジン |
Country Status (20)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4139284A1 (en) | 2020-04-22 | 2023-03-01 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| WO2023041432A1 (en) | 2021-09-14 | 2023-03-23 | Boehringer Ingelheim International Gmbh | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament |
| CN119143731B (zh) * | 2024-09-13 | 2025-08-26 | 中国海洋大学 | 一种吡嗪酰胺类化合物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2361149A1 (en) | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | Aromatic amides |
| JPWO2009107391A1 (ja) | 2008-02-27 | 2011-06-30 | 武田薬品工業株式会社 | 6員芳香環含有化合物 |
| GB0808668D0 (en) * | 2008-05-13 | 2008-06-18 | Univ Aberdeen | Materials and methods relating to a G-protein coupled receptor |
| EP2298731A4 (en) | 2008-06-25 | 2011-09-21 | Takeda Pharmaceutical | AMIDE COMPOUND |
| EP2518054A1 (en) * | 2009-12-24 | 2012-10-31 | Takeda Pharmaceutical Company Limited | Amide compound |
| EP2530078A1 (en) | 2010-01-27 | 2012-12-05 | Takeda Pharmaceutical Company Limited | Thiazole derivative |
| WO2011145735A1 (ja) | 2010-05-21 | 2011-11-24 | 武田薬品工業株式会社 | チアゾール誘導体 |
| WO2012020738A1 (ja) | 2010-08-09 | 2012-02-16 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2012076063A1 (en) | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| MX373876B (es) * | 2015-04-29 | 2020-03-26 | Arena Pharm Inc | 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas. |
| AU2016324317A1 (en) * | 2015-09-17 | 2018-03-08 | Coda Biotherapeutics, Inc. | Compositions and methods for treating neurological disorders |
-
2021
- 2021-03-29 CA CA3176265A patent/CA3176265A1/en active Pending
- 2021-03-29 US US17/215,759 patent/US11780827B2/en active Active
- 2021-03-29 AR ARP210100766A patent/AR121675A1/es not_active Application Discontinuation
- 2021-03-29 TW TW110111402A patent/TW202204343A/zh unknown
- 2021-03-29 JP JP2022559709A patent/JP7617134B2/ja active Active
- 2021-03-29 IL IL296823A patent/IL296823A/en unknown
- 2021-03-29 BR BR112022018996A patent/BR112022018996A2/pt not_active Application Discontinuation
- 2021-03-29 KR KR1020227038002A patent/KR20220161454A/ko not_active Withdrawn
- 2021-03-29 WO PCT/EP2021/058099 patent/WO2021198149A1/en not_active Ceased
- 2021-03-29 MX MX2022012067A patent/MX2022012067A/es unknown
- 2021-03-29 EP EP21716133.0A patent/EP4126850B1/en active Active
- 2021-03-29 AU AU2021250303A patent/AU2021250303A1/en not_active Abandoned
- 2021-03-29 CN CN202180025462.7A patent/CN115697997B/zh active Active
- 2021-03-29 CR CR20220554A patent/CR20220554A/es unknown
- 2021-03-29 PH PH1/2022/552553A patent/PH12022552553A1/en unknown
- 2021-03-29 PE PE2022002146A patent/PE20221918A1/es unknown
-
2022
- 2022-09-23 DO DO2022000203A patent/DOP2022000203A/es unknown
- 2022-09-28 JO JOJO/P/2022/0235A patent/JOP20220235A1/ar unknown
- 2022-10-18 EC ECSENADI202280683A patent/ECSP22080683A/es unknown
- 2022-10-19 CO CONC2022/0014886A patent/CO2022014886A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004534816A5 (cg-RX-API-DMAC7.html) | ||
| JP2020183410A5 (cg-RX-API-DMAC7.html) | ||
| TWI657078B (zh) | 作爲單胺氧化酶(mao)抑制劑之經取代之萘啶及喹啉化合物 | |
| IL298871A (en) | The composition consisting of the benzoate salt of 5-methoxy-N,N-dimethyltryptamine | |
| RU2012140148A (ru) | (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения | |
| JP2009524676A5 (cg-RX-API-DMAC7.html) | ||
| ES2971230T3 (es) | Compuestos inhibidores de VMAT2 y composiciones de los mismos | |
| JP2009534368A5 (cg-RX-API-DMAC7.html) | ||
| JP2018507877A5 (cg-RX-API-DMAC7.html) | ||
| FI3856182T3 (fi) | Koostumuksia ja menetelmiä muskariinireseptorin aktivaation lievittämien häiriöiden hoitamiseksi | |
| JP2010529081A5 (cg-RX-API-DMAC7.html) | ||
| JP2018519351A5 (cg-RX-API-DMAC7.html) | ||
| JP2007516193A5 (cg-RX-API-DMAC7.html) | ||
| JP2011524850A5 (cg-RX-API-DMAC7.html) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法 | |
| JP2017528515A5 (cg-RX-API-DMAC7.html) | ||
| JP2007532637A5 (cg-RX-API-DMAC7.html) | ||
| JP2022539152A5 (cg-RX-API-DMAC7.html) | ||
| AU2014364565B2 (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis | |
| WO2011097946A1 (zh) | 含有并环稠合双环的噁唑烷酮化合物及其制备和应用 | |
| JP2003513071A5 (cg-RX-API-DMAC7.html) | ||
| US20180244623A1 (en) | N-methyl-D-aspartate Receptor (NMDAR) Potentiators, Pharmaceutical Compositions, And Uses Related Thereto | |
| JP2022180531A5 (cg-RX-API-DMAC7.html) | ||
| RU2004117211A (ru) | Способы лечения депресии и других рассстройств цнс с использованием энантиомерно обогащшенных десметил-и дидесметилметаболитов циталопрама | |
| US20080096867A1 (en) | Imidazo[1,2-A] Pyridine Anxiolytics |